Compare Ascendis Pharma A/S (ASND) vs Clorox Co (CLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Clorox Co — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Clorox Co trades at $96.95 (market cap $11.68B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Clorox Co pays a 5.14% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CLX | |
|---|---|---|
Market Cap | $17.74B | $11.68B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $131.43 |
52-Week Low | $163.32 | $86.12 |
Enterprise Value | $18.11B | $14.98B |
Dividend Yield | — | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Clorox (CLX) trades at $96.56, up 3.75% today, but remains down over 7% YTD amid declining sales and profitability concerns. The stock shows a bearish technical trend with key support at $91, while fundamentals reveal strong profitability with an 11.18% net margin and a 5.5% dividend yield. Recent corporate actions include a simplified operating structure and CEO transition, with Q2 2026 earnings pending.
The outlook is mixed: a high dividend and recent earnings beats offer value, but bearish analyst sentiment and sales declines pose risks. Upside exists if restructuring drives growth, yet investor caution is warranted given valuation premiums and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
